Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio de la eficacia y seguridad de ruxolitinib en pacientes con enfermedad aguda de injerto contra huésped refractaria a esteroides de grado II a IV

6 de noviembre de 2026 actualizado por: Novartis Pharmaceuticals

Un estudio multicéntrico de un solo grupo de ruxolitinib para el tratamiento de pacientes chinos con enfermedad aguda de injerto contra huésped refractaria a corticosteroides de grado II-IV

The purpose of this study is to assess the efficacy and safety of ruxolitinib therapy in Chinese adults and adolescents (≥ 12 years old) with Grade II-IV steroid-refractory acute graft versus host disease (SR-aGvHD).

Descripción general del estudio

Estado

Activo, no reclutando

Intervención / Tratamiento

Descripción detallada

Participants will start with a screening period to assess the eligibility; only participants who meet all the inclusion and none of the exclusion criteria will start study treatment from Day 1 to Week 24 or end of treatment. Following safety follow up visits, participants will receive the long-term follow-up until Month 12.

Tipo de estudio

Intervencionista

Inscripción (Actual)

36

Fase

  • Fase 4

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Beijing, Porcelana, 100034
        • Novartis Investigative Site
      • Beijing, Porcelana, 100070
        • Novartis Investigative Site
      • Taian, Porcelana, 271000
        • Novartis Investigative Site
      • Tianjin, Porcelana, 300020
        • Novartis Investigative Site
    • Guangdong
      • Guangzhou, Guangdong, Porcelana, 510515
        • Novartis Investigative Site
    • Henan
      • Zhengzhou, Henan, Porcelana, 450003
        • Novartis Investigative Site
    • Hubei
      • Wuhan, Hubei, Porcelana, 430030
        • Novartis Investigative Site
    • Shanxi
      • Xian, Shanxi, Porcelana, 710061
        • Novartis Investigative Site
    • Zhejiang
      • Hangzhou, Zhejiang, Porcelana, 310003
        • Novartis Investigative Site

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

12 años a 100 años (Niño, Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Key Inclusion criteria

  • Male or female Chinese participants aged 12 or older at the time of informed consent. Written informed consent from participant, parent or legal guardian.

  • Able to swallow tablets.

  • Have undergone alloSCT from any donor source (matched unrelated donor, sibling, haplo-identical) using bone marrow, peripheral blood stem cells, or cord blood.

  • Clinically diagnosed Grades II to IV acute GvHD as per standard criteria occurring after alloSCT requiring systemic immune suppressive therapy.

  • Evident myeloid and platelet engraftment (confirmed within 48 hours prior to study treatment (ruxolitinib) start):

  • Confirmed diagnosis of steroid refractory aGvHD defined as participants administered systemic corticosteroids (methylprednisolone at least 1 mg/kg/day [or equivalent prednisone dose at least 1.25 mg/kg/day]), given alone or combined with calcineurin inhibitors (CNI) and either:

    1. Progression based on organ assessment after at least 3 days compared to organ stage at the time of initiation of systemic corticosteroid +/- CNI for the treatment of Grade II to IV aGvHD. OR

    2. Failure to achieve at a minimum partial response based on organ assessment after 7 days compared to organ stage at the time of initiation of systemic corticosteroid +/-CNI for the treatment of Grade II to IV. OR

    3. Participants who fail corticosteroid taper defined as fulfilling either one of the following criteria:

      • Requirement for an increase in the corticosteroid dose to methylprednisolone ≥ 1 mg/kg/day (or equivalent prednisone dose ≥ 1.25 mg/kg/day). OR
      • Failure to taper the methylprednisolone dose to < 0.5 mg/kg/day (or equivalent prednisone dose <0.6 mg/kg/day) for a minimum of 7 days.

Key Exclusion criteria

  • Has received more than one systemic treatment for steroid refractory aGvHD. Participants who received JAK inhibitor therapy for any indication after initiation of current alloSCT conditioning.
  • Clinical presentation resembling de novo chronic GvHD or GvHD overlap syndrome with both acute and chronic GvHD features.
  • Failed prior alloSCT within the past 6 months. Presence of relapsed primary malignancy after the alloSCT was performed.
  • Presence of an active uncontrolled infection including significant bacterial, fungal, viral or parasitic infection requiring treatment.
  • SR-aGvHD occurring after non-scheduled donor lymphocyte infusion (DLI) administered for pre-emptive treatment of malignancy recurrence. Note: Participants who have received a scheduled DLI as part of their transplant procedure and not for management of malignancy relapse are eligible.
  • Presence of significant respiratory disease, severely impaired renal function, clinically significant or uncontrolled cardiac disease, unresolved cholestatic and liver disorders (not attributable to aGvHD). Disorders and/or current therapy with medications that interfere with coagulation or platelet function.

Other protocol-defined inclusion / exclusion criteria may apply

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Ruxolitinib

Participants will receive ruxolitinib orally of 10 mg BID daily (given as two 5-mg tablets, approximately 12 hours apart).

Ruxolitinib is taken orally daily at 10 mg BID, given as two 5-mg tablets.

Otros nombres:
  • INC424

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Overall Response Rate (ORR) at Day 28 per Investigators
Periodo de tiempo: Day 28

The ORR at Day 28 defined as the percentage of participants demonstrating a complete response (CR) or partial response (PR) without requirement for additional systemic therapies for an earlier progression, mixed response or nonresponse, according to standard criteria and assessed by investigators.

Day 28

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Durable Overall response rate (ORR) at Day 56
Periodo de tiempo: Day 56

Durable ORR at Day 56 is defined as the percentage of participants who achieve a complete response (CR) or partial response (PR) at Day 28 and maintain a CR or PR at Day 56.

Day 56
Duration of Response (DOR)
Periodo de tiempo: From Week 1 to long term follow up Month 12

DOR is defined as the time from first response until aGvHD progression or the date of additional systemic therapies for aGvHD.

From Week 1 to long term follow up Month 12
Best overall response (BOR)
Periodo de tiempo: From week 1 to Day 28

Percentage of participants who achieved overall response (complete response (CR) + Partial response (PR) at any time point up to and including Day 28 and before the start of additional systemic therapy for aGvHD.

From week 1 to Day 28
Overall survival (OS)
Periodo de tiempo: From the date of start of study treatment to date of death, up to approx. 12 months

Overall survival (OS) is defined as the time from the date of start of study treatment to date of death due to any cause.

From the date of start of study treatment to date of death, up to approx. 12 months
Non-relapse mortality (NRM)
Periodo de tiempo: From date of start of study treatment to date of death, up to approx. 12 months

Non-relapse mortality (NRM) is defined as the time from date of start of study treatment to date of death not preceded by hematologic disease relapse/progression.

From date of start of study treatment to date of death, up to approx. 12 months
Event-free survival (EFS)
Periodo de tiempo: From the date of start of study treatment to the date of hematologic disease relapse/progression, graft failure, or death, up to approx. 12 months

Event-free survival (EFS) is defined as the time from the date of start of study treatment to the date of hematologic disease relapse/progression, graft failure, or death due to any cause.

From the date of start of study treatment to the date of hematologic disease relapse/progression, graft failure, or death, up to approx. 12 months
Failure-free survival (FFS)
Periodo de tiempo: From the date of start of study treatment to date of hematologic disease relapse/progression, non-relapse mortality, or addition of new systemic aGvHD treatment, up to approx. 12 months

Failure-free survival (FFS) is defined as the time from the date of start of study treatment to date of hematologic disease relapse/progression, non-relapse mortality, or addition of new systemic aGvHD treatment.

From the date of start of study treatment to date of hematologic disease relapse/progression, non-relapse mortality, or addition of new systemic aGvHD treatment, up to approx. 12 months
Malignancy Relapse/Progression (MR)
Periodo de tiempo: From date of start of study treatment to hematologic malignancy relapse/progression, up to approx. 12 months

Malignancy Relapse/Progression (MR) is defined as the time from date of start of study treatment to hematologic malignancy relapse/progression. Calculated for participants with underlying hematologic malignant disease.

From date of start of study treatment to hematologic malignancy relapse/progression, up to approx. 12 months
Reduction of daily corticosteroids dose
Periodo de tiempo: Up to Day 56

This includes the assessment of systemic corticosteroid use and daily dose, and the percentage of participants successfully tapered off all systemic corticosteroids until Day 56, by time intervals and overall.

Up to Day 56
Cumulative incidence of chronic GvHD
Periodo de tiempo: From Week 1 to long term follow up of month 12

Cumulative incidence of chronic GvHD (cGvHD) includes mild, moderate and severe occurrences.

From Week 1 to long term follow up of month 12

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Director de estudio: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

4 de julio de 2024

Finalización primaria (Actual)

3 de septiembre de 2026

Finalización del estudio (Estimado)

8 de julio de 2027

Fechas de registro del estudio

Enviado por primera vez

5 de junio de 2024

Primero enviado que cumplió con los criterios de control de calidad

14 de junio de 2024

Publicado por primera vez (Actual)

17 de junio de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

9 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

6 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • CINC424C2416

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir